Duncan Edwards
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Duncan Edwards has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Mant
Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
9 shared publications - Catherine L. Saunders
Department of Public Health and Primary Care, University of Cambridge
3 shared publications Simon Griffin
Department of Public Health and Primary Care, University of Cambridge
3 shared publicationsCarol Brayne
Institute of Public Health, School of Clinical Medicine, University of Cambridge, Cambridge, UK
2 shared publications- Christi Deaton
Primary Care Unit, Department of Public Health & Primary Care, University of Cambridge, Cambridge, UK
2 shared publications Fd Richard Hobbs
Nuffield Professor of Primary Care Health Sciences, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
2 shared publications
Latest Publications
- Open Access
- 5 May 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (736) , e825-e831
Progression of stroke risk in patients aged <65 years diagnosed with atrial fibrillation: a cohort study in general practice
Background: As a result of new technologies, atrial fibrillation (AF) is more likely to be diagnosed in people aged 2DS2-VASc score was derived at time of diagnosis based on patients’ medical records. Patients not eligible for anticoagulation were followed up until they became eligible or turned 65 years old. The primary outcome of interest was development of a risk factor for stroke in AF.Results: Among 18 178 patients aged <65 years diagnosed with AF, 9188 (50.5%) were eligible for anticoagulation at the time of diagnosis. Among the 8990 patients not eligible for anticoagulation, 1688 (18.8%) developed a risk factor during follow-up before reaching 65 years of age or leaving the cohort for other reasons, at a rate of 6.1 per 100 patient-years. Hypertension and heart failure were the most common risk factors to occur, with rates of 2.65 (95% CI = 2.47 to 2.84) and 1.58 (95% CI = 1.45 to 1.72) per 100 patient-years, respectively. The rate of new diabetes was 0.95 (95% CI = 0.85 to 1.06) per 100 patient-years.Conclusion: People aged <65 years with AF are at higher risk of developing hypertension, heart failure, and diabetes than the general population, so may warrant regular review to identify new occurrence of such risk factors.
- 5 May 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (736) , e825-e831
Open AccessProgression of stroke risk in patients aged <65 years diagnosed with atrial fibrillation: a cohort study in general practice
Background: As a result of new technologies, atrial fibrillation (AF) is more likely to be diagnosed in people aged 2DS2-VASc score was derived at time of diagnosis based on patients’ medical records. Patients not eligible for anticoagulation were followed up until they became eligible or turned 65 years old. The primary outcome of interest was development of a risk factor for stroke in AF.Results: Among 18 178 patients aged <65 years diagnosed with AF, 9188 (50.5%) were eligible for anticoagulation at the time of diagnosis. Among the 8990 patients not eligible for anticoagulation, 1688 (18.8%) developed a risk factor during follow-up before reaching 65 years of age or leaving the cohort for other reasons, at a rate of 6.1 per 100 patient-years. Hypertension and heart failure were the most common risk factors to occur, with rates of 2.65 (95% CI = 2.47 to 2.84) and 1.58 (95% CI = 1.45 to 1.72) per 100 patient-years, respectively. The rate of new diabetes was 0.95 (95% CI = 0.85 to 1.06) per 100 patient-years.Conclusion: People aged <65 years with AF are at higher risk of developing hypertension, heart failure, and diabetes than the general population, so may warrant regular review to identify new occurrence of such risk factors.
- Open Access
Sociodemographic Characteristics and Longitudinal Progression of Multimorbidity: A Multistate Modelling Analysis of a Large Primary Care Records Dataset in England
Background Multimorbidity presents a growing public health challenge. While existing research has mainly focused on cross-sectional patterns of multimorbidity, there remains a need to better understand the longitudinal accumulation of diseases and the effects of important sociodemographic characteristics on the accumulation and progression of chronic conditions. Methods and findings We use a spline-based parametric multistate modelling (MSM) framework for investigating the role of several sociodemographic characteristics such as ethnicity, deprivation, gender, and age on the rate of disease transitions along different pathways to multimorbidity accumulation. The model is highly flexible and permits a parallel estimation framework that scales well to very large datasets. Focusing on cardiometabolic, renal conditions and mental conditions, we analysed a dataset of about 13 million English electronic primary care records. Our results revealed complex interactions between temporal trajectories of multimorbidity and the sociodemographic factors, with effects that varied depending on the comorbidity status of the subject. These factors tended to have a larger impact on initial multimorbidity development while a smaller impact on later stages. Mental health as a comorbidity often strengthened the adverse effects of sociodemographic characteristics on disease accumulation. Conclusion Our findings underscore the potential importance of earlier screening and intervention of chronic conditions, particular for mental health conditions, in the higher-risk populations. This may have important implications for the management of multimorbidity.
Open AccessSociodemographic Characteristics and Longitudinal Progression of Multimorbidity: A Multistate Modelling Analysis of a Large Primary Care Records Dataset in England
Background Multimorbidity presents a growing public health challenge. While existing research has mainly focused on cross-sectional patterns of multimorbidity, there remains a need to better understand the longitudinal accumulation of diseases and the effects of important sociodemographic characteristics on the accumulation and progression of chronic conditions. Methods and findings We use a spline-based parametric multistate modelling (MSM) framework for investigating the role of several sociodemographic characteristics such as ethnicity, deprivation, gender, and age on the rate of disease transitions along different pathways to multimorbidity accumulation. The model is highly flexible and permits a parallel estimation framework that scales well to very large datasets. Focusing on cardiometabolic, renal conditions and mental conditions, we analysed a dataset of about 13 million English electronic primary care records. Our results revealed complex interactions between temporal trajectories of multimorbidity and the sociodemographic factors, with effects that varied depending on the comorbidity status of the subject. These factors tended to have a larger impact on initial multimorbidity development while a smaller impact on later stages. Mental health as a comorbidity often strengthened the adverse effects of sociodemographic characteristics on disease accumulation. Conclusion Our findings underscore the potential importance of earlier screening and intervention of chronic conditions, particular for mental health conditions, in the higher-risk populations. This may have important implications for the management of multimorbidity.
- Open Access
- 11 October 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 152, 164-175
In simulated data and health records, latent class analysis was the optimum multimorbidity clustering algorithm
- 11 October 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 152, 164-175
Open AccessIn simulated data and health records, latent class analysis was the optimum multimorbidity clustering algorithm
- Open Access
- 22 July 2021
- Published by Springer Nature in Drug Safety
- Vol. 44 (10) , 1033-1040
Use of Primary Care Data in Research and Pharmacovigilance: Eight Scenarios Where Prescription Data are Absent
The use of primary care databases has been integral in pharmacoepidemiological studies and pharmacovigilance. Primary care databases derive from electronic health records and offer a comprehensive description of aggregate patient data, from demography to medication history, and good sample sizes. Studies using these databases improve our understanding of prescribing characteristics and associated risk factors to facilitate better patient care, but there are limitations. We describe eight key scenarios where study data outcomes can be affected by absent prescriptions in UK primary care databases: (1) out-of-hours, urgent care and acute care prescriptions; (2) specialist-only prescriptions; (3) alternative community prescribing, such as pharmacy, family planning clinic or sexual health clinic medication prescriptions; (4) newly licensed medication prescriptions; (5) medications that do not require prescriptions; (6) hospital inpatient and outpatient prescriptions; (7) handwritten prescriptions; and (8) private pharmacy and private doctor prescriptions. The significance of each scenario is dependent on the type of medication under investigation, nature of the study and expected outcome measures. We recommend that all researchers using primary care databases be aware of the potential for missing prescribing data and be sensitive to how this can vary substantially between items, drug classes, patient groups and over time. Close liaison with practising primary care clinicians in the UK is often essential to ensure awareness of nuances in clinical practice.
- 22 July 2021
- Published by Springer Nature in Drug Safety
- Vol. 44 (10) , 1033-1040
Open AccessUse of Primary Care Data in Research and Pharmacovigilance: Eight Scenarios Where Prescription Data are Absent
The use of primary care databases has been integral in pharmacoepidemiological studies and pharmacovigilance. Primary care databases derive from electronic health records and offer a comprehensive description of aggregate patient data, from demography to medication history, and good sample sizes. Studies using these databases improve our understanding of prescribing characteristics and associated risk factors to facilitate better patient care, but there are limitations. We describe eight key scenarios where study data outcomes can be affected by absent prescriptions in UK primary care databases: (1) out-of-hours, urgent care and acute care prescriptions; (2) specialist-only prescriptions; (3) alternative community prescribing, such as pharmacy, family planning clinic or sexual health clinic medication prescriptions; (4) newly licensed medication prescriptions; (5) medications that do not require prescriptions; (6) hospital inpatient and outpatient prescriptions; (7) handwritten prescriptions; and (8) private pharmacy and private doctor prescriptions. The significance of each scenario is dependent on the type of medication under investigation, nature of the study and expected outcome measures. We recommend that all researchers using primary care databases be aware of the potential for missing prescribing data and be sensitive to how this can vary substantially between items, drug classes, patient groups and over time. Close liaison with practising primary care clinicians in the UK is often essential to ensure awareness of nuances in clinical practice.
- 1 January 2020
- Published by Elsevier in Ageing Research Reviews
- Vol. 57, 100962
Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: A systematic review and meta-analysis
- 1 January 2020
- Published by Elsevier in Ageing Research Reviews
- Vol. 57, 100962
Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: A systematic review and meta-analysis
- Open Access
- 26 November 2019
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 3 (4)
Optimising Management of Patients with Heart Failure with Preserved Ejection Fraction in Primary Care (OPTIMISE-HFpEF): rationale and protocol for a multi-method study
Background: Heart failure with preserved ejection fraction (HFpEF) is less well understood than heart failure with reduced ejection fraction (HFrEF), with greater diagnostic difficulty and management uncertainty.Aim: The primary aim is to develop an optimised programme that is informed by the needs and experiences of people with HFpEF and healthcare providers. This article presents the rationale and protocol for the Optimising Management of Patients with Heart Failure with Preserved Ejection Fraction in Primary Care (OPTIMISE-HFpEF) research programme.Design & setting: This is a multi-method programme of research conducted in the UK.Method: OPTIMISE-HFpEF is a multi-site programme of research with three distinct work packages (WPs). WP1 is a systematic review of heart failure disease management programmes (HF-DMPs) tested in patients with HFpEF. WP2 has three components (a, b, c) that enable the characteristics, needs, and experiences of people with HFpEF, their carers, and healthcare providers to be understood. Qualitative enquiry (WP2a) with patients and providers will be conducted in three UK sites exploring patient and provider perspectives, with an additional qualitative component (WP2c) in one site to focus on transitions in care and carer perspectives. A longitudinal cohort study (WP2b), recruiting from four UK sites, will allow patients to be characterised and their illness trajectory observed across 1 year of follow-up. Finally, WP3 will synthesise the findings and conduct work to gain consensus on how best to identify and manage this patient group.Results: Results from the four work packages will be synthesised to produce a summary of key learning points and possible solutions (optimised programme) which will be presented to a broad spectrum of stakeholders to gain consensus on a way forward.Conclusion: HFpEF is often described as the greatest unmet need in cardiology. The OPTIMISE-HFpEF programme aims to address this need in primary care, which is arguably the most appropriate setting for managing HFpEF.
- 26 November 2019
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 3 (4)
Open AccessOptimising Management of Patients with Heart Failure with Preserved Ejection Fraction in Primary Care (OPTIMISE-HFpEF): rationale and protocol for a multi-method study
Background: Heart failure with preserved ejection fraction (HFpEF) is less well understood than heart failure with reduced ejection fraction (HFrEF), with greater diagnostic difficulty and management uncertainty.Aim: The primary aim is to develop an optimised programme that is informed by the needs and experiences of people with HFpEF and healthcare providers. This article presents the rationale and protocol for the Optimising Management of Patients with Heart Failure with Preserved Ejection Fraction in Primary Care (OPTIMISE-HFpEF) research programme.Design & setting: This is a multi-method programme of research conducted in the UK.Method: OPTIMISE-HFpEF is a multi-site programme of research with three distinct work packages (WPs). WP1 is a systematic review of heart failure disease management programmes (HF-DMPs) tested in patients with HFpEF. WP2 has three components (a, b, c) that enable the characteristics, needs, and experiences of people with HFpEF, their carers, and healthcare providers to be understood. Qualitative enquiry (WP2a) with patients and providers will be conducted in three UK sites exploring patient and provider perspectives, with an additional qualitative component (WP2c) in one site to focus on transitions in care and carer perspectives. A longitudinal cohort study (WP2b), recruiting from four UK sites, will allow patients to be characterised and their illness trajectory observed across 1 year of follow-up. Finally, WP3 will synthesise the findings and conduct work to gain consensus on how best to identify and manage this patient group.Results: Results from the four work packages will be synthesised to produce a summary of key learning points and possible solutions (optimised programme) which will be presented to a broad spectrum of stakeholders to gain consensus on a way forward.Conclusion: HFpEF is often described as the greatest unmet need in cardiology. The OPTIMISE-HFpEF programme aims to address this need in primary care, which is arguably the most appropriate setting for managing HFpEF.
- Open Access
Characteristics, service use and mortality of clusters of multimorbid patients in England: a population-based study
Background: Multimorbidity is one of the principal challenges facing health systems worldwide. To help understand the changes to services and policies that are required to deliver better care, we used a novel approach to investigate which diseases co-occur and how combinations are associated with mortality and service use. Methods: Linked primary and secondary care electronic health records contributed by 382 general practices in England to the Clinical Practice Research Datalink (CPRD) were used. The study included a representative set of multimorbid adults (18 years old or more) with two or more long-term conditions (N=113,211). A random set of 80% of the multimorbid patients (N=90,571) were stratified by age and clustered using latent class analysis. Consistency between obtained disease profiles, classification quality and associations with demographic characteristics and primary outcomes (hospitalisation, polypharmacy and mortality) was validated in the remaining 20% of multimorbid patients (N=22,640). Findings: We identified twenty patient clusters across four age strata. The clusters with the highest mortality comprised psychoactive substance and alcohol misuse (aged 18-64), coronary heart disease, depression and pain (aged 65-84) and coronary heart disease, heart failure and atrial fibrillation (aged 85+). The clusters with the highest service use coincided with those with highest mortality for people aged over 65. For people aged 18-64, the cluster with the highest service use comprised depression, anxiety and pain. The majority of 85+ year olds multimorbid patients belonged to the cluster with the lowest service use and mortality for that age range. Pain featured in thirteen clusters. Interpretation: This work has highlighted patterns of multimorbidity that have implications for health services. These include the importance of psychoactive substance and alcohol misuse in people under the age of 65; of co-morbid depression and coronary heart disease in people aged 65-84, and of cardiovascular disease in people aged 85+. Funding: UK Medical Research Council Research in context: Evidence before this study: We searched PubMed using the keyword list “multimorbidity, co-morbidity, disease patterns, clusters, service use, long-term conditions, chronic conditions” for studies published in English. We also reviewed multiple systematic reviews of multimorbidity patterns, and the policy report of multimorbidity research issued by the Academy of Medical Sciences in 2018. Most studies have focused on older populations (aged 60+) and often used a small list of long-term conditions. Multimorbidity clusters composed of more than two conditions have not been well profiled mostly due to non-representative and small samples. There is substantial heterogeneity in the number of conditions considered (often less than 20) and in the statistical methods. Most studies focused on grouping diseases rather than patients, making it less straightforward to relate patients to outcomes in order to facilitate patient-centred care. Added value of this study: This study is the first to describe and validate clusters of multimorbid patients across the adult lifecourse using a patient-centred probabilistic clustering approach. This leads to a more nuanced understanding of the relationship between age, multimorbidity and mortality and new insights into the importance of different clusters. For example, contrary to perceived wisdom, we show that the majority of 85+ year old multimorbid patients belong to a cluster with relatively low service use and mortality for that age group. We identify a cluster of younger multimorbid patients with psychoactive substance misuse that have a mortality rate 18 times higher than their non-multimorbid peers. Implications of all the available evidence: We have validated and added to the list of disease combinations where tailored approaches could be attempted to better manage multimorbid patients and develop effective interventions. For example, the high mortality of younger multimorbid patients with psychoactive substance misuse might be reduced by addressing risk factors (e.g. drug use, smoking, deprivation) which are amenable to intervention.
Open AccessCharacteristics, service use and mortality of clusters of multimorbid patients in England: a population-based study
Background: Multimorbidity is one of the principal challenges facing health systems worldwide. To help understand the changes to services and policies that are required to deliver better care, we used a novel approach to investigate which diseases co-occur and how combinations are associated with mortality and service use. Methods: Linked primary and secondary care electronic health records contributed by 382 general practices in England to the Clinical Practice Research Datalink (CPRD) were used. The study included a representative set of multimorbid adults (18 years old or more) with two or more long-term conditions (N=113,211). A random set of 80% of the multimorbid patients (N=90,571) were stratified by age and clustered using latent class analysis. Consistency between obtained disease profiles, classification quality and associations with demographic characteristics and primary outcomes (hospitalisation, polypharmacy and mortality) was validated in the remaining 20% of multimorbid patients (N=22,640). Findings: We identified twenty patient clusters across four age strata. The clusters with the highest mortality comprised psychoactive substance and alcohol misuse (aged 18-64), coronary heart disease, depression and pain (aged 65-84) and coronary heart disease, heart failure and atrial fibrillation (aged 85+). The clusters with the highest service use coincided with those with highest mortality for people aged over 65. For people aged 18-64, the cluster with the highest service use comprised depression, anxiety and pain. The majority of 85+ year olds multimorbid patients belonged to the cluster with the lowest service use and mortality for that age range. Pain featured in thirteen clusters. Interpretation: This work has highlighted patterns of multimorbidity that have implications for health services. These include the importance of psychoactive substance and alcohol misuse in people under the age of 65; of co-morbid depression and coronary heart disease in people aged 65-84, and of cardiovascular disease in people aged 85+. Funding: UK Medical Research Council Research in context: Evidence before this study: We searched PubMed using the keyword list “multimorbidity, co-morbidity, disease patterns, clusters, service use, long-term conditions, chronic conditions” for studies published in English. We also reviewed multiple systematic reviews of multimorbidity patterns, and the policy report of multimorbidity research issued by the Academy of Medical Sciences in 2018. Most studies have focused on older populations (aged 60+) and often used a small list of long-term conditions. Multimorbidity clusters composed of more than two conditions have not been well profiled mostly due to non-representative and small samples. There is substantial heterogeneity in the number of conditions considered (often less than 20) and in the statistical methods. Most studies focused on grouping diseases rather than patients, making it less straightforward to relate patients to outcomes in order to facilitate patient-centred care. Added value of this study: This study is the first to describe and validate clusters of multimorbid patients across the adult lifecourse using a patient-centred probabilistic clustering approach. This leads to a more nuanced understanding of the relationship between age, multimorbidity and mortality and new insights into the importance of different clusters. For example, contrary to perceived wisdom, we show that the majority of 85+ year old multimorbid patients belong to a cluster with relatively low service use and mortality for that age group. We identify a cluster of younger multimorbid patients with psychoactive substance misuse that have a mortality rate 18 times higher than their non-multimorbid peers. Implications of all the available evidence: We have validated and added to the list of disease combinations where tailored approaches could be attempted to better manage multimorbid patients and develop effective interventions. For example, the high mortality of younger multimorbid patients with psychoactive substance misuse might be reduced by addressing risk factors (e.g. drug use, smoking, deprivation) which are amenable to intervention.
- Open Access
- 1 June 2019
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 11, 495-508
Statin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study
Background: Trial evidence supports statin use after ischemic stroke and recent American, European and British guidelines recommend high-intensity statins for this indication. Limited data are available describing current statin use among these patients in unselected settings. We conducted a cohort study to examine secular trends and factors associated with statin use and dose following ischemic stroke. Methods: A retrospective cohort study of patients with first ischemic stroke between 2000 and 2014 was conducted using the Clinical Practice Research Datalink (CPRD). Proportions of statin users and high-intensity statin users within 2 years after stroke were estimated for each calendar year. We used Cox regression models to explore potential factors associated with statin use and Poisson regression models to calculate risk ratios for the use of a high-intensity statin. Results: A total of 80,442 patients with first stroke were analyzed. The proportion using statins within 2 years after stroke increased from 25% in 2000 to 70% in 2006 and remained at about 75% through 2014. Among post-stroke statin users, high-intensity use accounted for approximately 15% between 2004 and 2011 and then increased to almost 35% in 2014. Older patients (aged ≥75 years), younger patients (Conclusion: There has been an increase over time in both statin use and dose, but many patients with ischemic stroke continue to be under-treated. Clinical trials and policy interventions to improve appropriate post-stroke statin use should focus on younger and older patients, patients with no pre-stroke statin treatment, and patients without additional cardiovascular risk factors.
- 1 June 2019
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 11, 495-508
Open AccessStatin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study
Background: Trial evidence supports statin use after ischemic stroke and recent American, European and British guidelines recommend high-intensity statins for this indication. Limited data are available describing current statin use among these patients in unselected settings. We conducted a cohort study to examine secular trends and factors associated with statin use and dose following ischemic stroke. Methods: A retrospective cohort study of patients with first ischemic stroke between 2000 and 2014 was conducted using the Clinical Practice Research Datalink (CPRD). Proportions of statin users and high-intensity statin users within 2 years after stroke were estimated for each calendar year. We used Cox regression models to explore potential factors associated with statin use and Poisson regression models to calculate risk ratios for the use of a high-intensity statin. Results: A total of 80,442 patients with first stroke were analyzed. The proportion using statins within 2 years after stroke increased from 25% in 2000 to 70% in 2006 and remained at about 75% through 2014. Among post-stroke statin users, high-intensity use accounted for approximately 15% between 2004 and 2011 and then increased to almost 35% in 2014. Older patients (aged ≥75 years), younger patients (Conclusion: There has been an increase over time in both statin use and dose, but many patients with ischemic stroke continue to be under-treated. Clinical trials and policy interventions to improve appropriate post-stroke statin use should focus on younger and older patients, patients with no pre-stroke statin treatment, and patients without additional cardiovascular risk factors.
- Open Access
- 21 May 2019
- Published by Springer Nature in BMC Family Practice
- Vol. 20 (1) , 67
The role of the GP in managing suspected transient ischaemic attack: a qualitative study
National guidelines recommend patients with suspected transient ischaemic attack (TIA) should be seen by a specialist within 24 h. However, people with suspected TIA often present to non-specialised services, particularly primary care. Therefore, general practitioners (GPs) have a crucial role in recognition and urgent referral of people with suspected TIA. This study aims to explore the role of GPs in the initial management of suspected TIA in the United Kingdom (UK). One-to-one, semi-structured interviews with GPs, TIA clinic staff and patients with suspected TIA from two sites in the UK: Cambridge and Birmingham. Thematic analysis was undertaken to explore views on the role of the GP in managing suspected TIA. Thirty semi-structured interviews were conducted with stroke patients (n = 12), GPs (n = 9) and TIA clinic hospital staff (n = 9) from two hospitals and nine GP practices in surrounding areas. Three overarching themes were identified: (1) multiple management pathways for suspected TIA; (2) uncertainty regarding suspected TIA as an emergency or routine situation; and (3) influences on the urgency of GP management. Guidelines on the primary care management of TIA describe only a small proportion of the factors which influence GP management and referral of suspected TIA. Efforts to improve treatment, appropriate referral and patient experience should use a real rather than idealised model of the GP role in managing suspected TIA.
- 21 May 2019
- Published by Springer Nature in BMC Family Practice
- Vol. 20 (1) , 67
Open AccessThe role of the GP in managing suspected transient ischaemic attack: a qualitative study
National guidelines recommend patients with suspected transient ischaemic attack (TIA) should be seen by a specialist within 24 h. However, people with suspected TIA often present to non-specialised services, particularly primary care. Therefore, general practitioners (GPs) have a crucial role in recognition and urgent referral of people with suspected TIA. This study aims to explore the role of GPs in the initial management of suspected TIA in the United Kingdom (UK). One-to-one, semi-structured interviews with GPs, TIA clinic staff and patients with suspected TIA from two sites in the UK: Cambridge and Birmingham. Thematic analysis was undertaken to explore views on the role of the GP in managing suspected TIA. Thirty semi-structured interviews were conducted with stroke patients (n = 12), GPs (n = 9) and TIA clinic hospital staff (n = 9) from two hospitals and nine GP practices in surrounding areas. Three overarching themes were identified: (1) multiple management pathways for suspected TIA; (2) uncertainty regarding suspected TIA as an emergency or routine situation; and (3) influences on the urgency of GP management. Guidelines on the primary care management of TIA describe only a small proportion of the factors which influence GP management and referral of suspected TIA. Efforts to improve treatment, appropriate referral and patient experience should use a real rather than idealised model of the GP role in managing suspected TIA.
- Open Access
- 1 November 2018
- Published by Elsevier in Indian Heart Journal
- Vol. 70 (6) , 828-835
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry
- 1 November 2018
- Published by Elsevier in Indian Heart Journal
- Vol. 70 (6) , 828-835
Open AccessRisk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry